Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications.
drug checking
fentanyl
harm reduction
test strips
xylazine
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
03 Dec 2023
03 Dec 2023
Historique:
revised:
03
11
2023
received:
01
09
2023
accepted:
06
11
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
3
12
2023
Statut:
aheadofprint
Résumé
The continued prevalence of xylazine in the illicit drug market has necessitated development of quick and simple methods for identification, including lateral flow immunoassays (also known as "test strips"), like those frequently used to detect fentanyl. This study explored the drug checking applicability of the first publicly available xylazine test strips (XTS) using four sub-studies: reproducibility (i.e., consistency of positive results in a highly-concentrated xylazine solution); limit of detection on a calibration curve of xylazine concentrations; cross-reactivity against 77 commonly encountered drugs, cutting agents, and other structurally similar compounds; and applicability for analyzing community-acquired samples-where 100 drug residue samples were analyzed using XTS, direct analysis in real time mass spectrometry (DART-MS), and gas chromatography tandem mass spectrometry (GC-MS/MS). XTS consistently detected xylazine at concentrations ≥2.5 μg/ml, and XTS results were reproducible. Sensitivity and specificity of XTS were calculated by comparing expected versus obtained results based on xylazine concentration of community-acquired samples measured by GC-MS/MS. XTS consistently detected xylazine in samples with concentration >2 μg/ml and yielded a sensitivity of 0.974, specificity of 1.00, and overall accuracy of 0.986. Cross-reactivity with lidocaine, a common cutting agent, and lack of XTS reactivity with other α
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Drug Enforcement Administration. Xylazine. Accessed February 21, 2023, https://www.deadiversion.usdoj.gov/drug_chem_info/Xylazine.pdf
Biden-Harris administration designates fentanyl combined with xylazine as an emerging threat to the United States. 2023. Accessed May 2, 2023. https://www.whitehouse.gov/ondcp/briefing-room/2023/04/12/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states/
Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
Kariisa M, Patel P, Smith H, Bitting J. Notes from the field: xylazine detection and involvement in drug overdose deaths-United States, 2019. Morb Mortal Wkly Rep. 2021;70(37):1300-1302. doi:10.15585/mmwr.mm7037a4
Maryland Xylazine Workgroup. Xylazine in Maryland: an initial report of the Maryland Xylazine Workgroup, 2022. 2023.
Reyes JC, Negrón J, Colón H, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012;89(3):519-526. doi:10.1007/s11524-011-9662-6
Malayala SV, Papudesi BN, Bobb R, Wimbush A. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14(8):1-6. doi:10.7759/cureus.28160
Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug Alcohol Depend Rep. 2022;4:100074.
Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the southeastern United States. Int J Drug Policy. 2019;63:122-128. doi:10.1016/j.drugpo.2018.08.007
Krotulski AJ, Shinefeld J, DeBord J, Teixeira da Silva D, Logan BK. Evaluation of Xylazine Test Strips (BTNX) for drug checking purposes 2023. Accessed May 19, 2023. https://www.cfsre.org/images/content/reports/drug_checking/Evaluation_of_BTNX_Xylazine_Test_Strips_for_Drug_Checking_230322.pdf
BTNX Inc. Xylazine test strip instructions https://www.btnx.com/files/HarmReduction/Instructions%20(EN)%20H10110397901-XYL-18S2-100%20&%2010.pdf
Lockwood T-LE, Vervoordt A, Lieberman M. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips. Harm Reduct J. 2021;18(1):1-9.
Appley MG, Robinson EL, Thomson A, Russell E, Sisco E. An analytical platform for near real-time drug landscape monitoring using paraphernalia residues. Forens Chem. 2023;34:100489. doi:10.1016/j.forc.2023.100489
CFSRE, NPS Discovery, Department of Public Health City of Philadelphia. Quarterly report-Philadelphia, PA: drug checking Q3 2022. 2022. https://www.cfsre.org/images/content/reports/drug_checking/2022_Q3_Drug_Checking_Quarterly_Report_Philadelphia.pdf
Hutchison A, Kielty C. Xylazine: a frank scope of ‘tranq-dope’. Substance Drug Checking blog. https://substance.uvic.ca/blog/xylazine/. 2022.
Fiorentin TR, Krotulski AJ, Martin DM, et al. Detection of cutting agents in drug-positive seized exhibits within the United States. J Forensic Sci. 2019;64(3):888-896. doi:10.1111/1556-4029.13968
Sisco E, Appley M. Identification of the veterinary sedative medetomidine in combination with opioids and xylazine in Maryland. J Forensic Sci. 2023;68(5):1708-1712. doi:10.1111/1556-4029.15242
Hayden JA, Schmeling M, Hoofnagle AN. Lot-to-lot variations in a qualitative lateral-flow immunoassay for chronic pain drug monitoring. Clin Chem. 2014;60(6):896-897. doi:10.1373/clinchem.2013.221028